高度な治療用医薬品CDMO市場 (2026 - 2035)

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed scientific journals, clinical trial registries, and authoritative biotechnology organizations. Key sources included the US Food & Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), European Medicines Agency (EMA) Committee for Advanced Therapies (CAT), International Society for Cell & Gene Therapy (ISCT), Alliance for Regenerative Medicine (ARM), National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS), National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, EU Clinical Trials Register, Organisation for Economic Co-operation and Development (OECD) Biotechnology Statistics, Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), and national regulatory authority reports from key markets including Medicines and Healthcare products Regulatory Agency (MHRA-UK), Pharmaceuticals and Medical Devices Agency (PMDA-Japan), National Medical Products Administration (NMPA-China), and Health Canada.

Clinical trial landscape analysis, GMP facility certifications, manufacturing capacity statistics, competitive intelligence on CDMO service portfolios, and regulatory approval data for CAR-T therapies, gene therapies, and stem cell treatments were all gathered from these sources.

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, Chief Technical Officers, Heads of Cell & Gene Therapy Manufacturing, Quality Assurance Directors, and Business Development Heads from ATMP-focused CDMOs, viral vector producers, and plasmid DNA providers were among the supply-side sources. Chief Scientific Officers, VPs of Technical Operations, Head of External Manufacturing, and procurement leads from biotechnology and pharmaceutical businesses creating tissue-engineered products, gene treatments, and cell therapies were examples of demand-side sources.

Primary research verified capacity expansion schedules and facility build-outs; validated market segmentation across vector manufacturing (lentiviral, AAV, retroviral), cell therapy processing (autologous, allogeneic), and analytical testing services; and acquired information on regulatory compliance tactics, pricing models for GMP manufacturing slots, and partnership structures between innovators and CDMOs.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)

Manufacturing capacity analysis and service revenue mapping were used to determine the global market valuation. The methodology comprised:

Finding more than fifty important CDMOs in emerging markets, North America, Europe, and Asia-Pacific

Service mapping for the creation of plasmid DNA, cell treatment (CAR-T, stem cells, iPSCs), fill-finish services, and viral vectors (AAV, lentiviral, retroviral).

Analysis of annual revenues for ATMP manufacturing portfolios, both reported and modeled

Coverage of CDMOs accounting for 75–80% of the world's ATMP production capacity in 2024

Extrapolation of segment-specific valuations for gene therapy CDMO, cell therapy CDMO, and viral vector manufacturing markets using top-down (CDMO revenue validation against reported client pipelines) and bottom-up (number of clinical/commercial programs × average contract value by phase) approaches